17 Increasing evidence shows convincible efficacy with HDC‐ASCT: the IELSG‐32 trial revealed a comparable response between WBRT and HDC‐ASCT, 6 and the PRECIS trial even showed a favorable trend of PFS in the HDC‐ASCT arm. 8 Our real‐world cohort demonstrated a similar treatment response between WBRT and HDC‐ASCT (Figure 3A,B ), and each arm of frontline intensification achieved two‐year PFS and OS rates of at least 60% and 70%, respectively.
← all excerpts
Long-term outcomes of frontline intensification in primary CNS lymphoma: A real-world single-center experience.
1
—
—